Recent Updates
Recently added Catalysts
CGON Positive Sentiment

BCAN Think Tank 2026 – Creto EAP Poster and Podium

Thursday, July 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology is set to present at the BCAN Think Tank 2026, showcasing their Creto EAP poster and podium. This event highlights their ongoing commitment to research and collaboration in the oncology field. Additionally, the company has recently published pivotal results from their Phase 3 BOND-003 study in The Lancet Oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology is actively participating in significant conferences.
  • The presentation of the BOND-003 study results indicates progress.
  • Engagement in the BCAN Think Tank shows commitment to collaboration.

Full Press Release Details

by admin | Jul 30, 2026 | congress-hub-posters

Recent Posts

• BCAN Think Tank 2026 – Creto EAP Poster and Podium
• THE LANCET ONCOLOGY 2026 PUBLICATION
• CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June

Recent Comments

Frequently Asked Questions

What is the BCAN Think Tank 2026?

The BCAN Think Tank 2026 is a conference focused on advancements in oncology.

What will CG Oncology present at the event?

CG Oncology will present their Creto EAP poster and podium at the BCAN Think Tank.

What recent study results did CG Oncology publish?

CG Oncology published pivotal results from their Phase 3 BOND-003 study in The Lancet Oncology.

When is the BCAN Think Tank 2026 taking place?

The specific date for the BCAN Think Tank 2026 is not mentioned in the article.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology Creto EAP BOND-003 oncology clinical research
Last updated: Jul 30, 2026

Biotech snapshot

Cash runway
$1076M liquidity · $19M/mo burn
~54 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →